23andMe
About: 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Employees: 582
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
68% more call options, than puts
Call options by funds: $141K | Put options by funds: $84K
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
6.65% less ownership
Funds ownership: 31.17% [Q2] → 24.53% (-6.65%) [Q3]
21% less funds holding
Funds holding: 145 [Q2] → 114 (-31) [Q3]
26% less capital invested
Capital invested by funds: $39.4M [Q2] → $29M (-$10.4M) [Q3]
49% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 37
78% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 40
Research analyst outlook
We haven’t received any recent analyst ratings for ME.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collaboration. Under the agreement, Mirador will leverage a targeted set of aggregated, de-identified genetic and phenotypic data from the 23andMe research database and its proprietary Mirador360™ development engine to enable target validation and precision medicine.
Neutral
Seeking Alpha
1 month ago
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
23andMe Holding Co. (NASDAQ:ME ) Q2 2025 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Katie Watson - Vice President, Communications Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the 23andMe Fiscal Year 2025 Second Quarter Earnings Call.
Negative
TechCrunch
1 month ago
23andMe cuts 40% of staff in restructuring
23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually.
Negative
Fast Company
1 month ago
What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its operations, with plans to lay off 200 employees, or roughly 40% of its workforce. The company also said it will discontinue development of its therapeutic programs.
Negative
CNBC
1 month ago
23andMe reports sales decline day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The embattled genetic testing company said Monday that it's cutting about 200 jobs, or about 40% of its workforce, and discontinuing its therapeutics programs.
Negative
The Guardian
1 month ago
Genetic testing firm 23andMe cuts 40% of its workforce amid financial struggles
Company says it will cut about 200 employees as value plummets in aftermath of huge data breach
Negative
Market Watch
1 month ago
23andMe's stock turns lower after company posts its latest quarterly loss
Stock had gained late Monday on news it would cut 40% of its workforce as part of a restructuring.
Negative
Proactive Investors
1 month ago
23andMe to cut 40% of its workforce as it looks to stablise the business
Genetic testing firm 23andMe announced plans to cut 40% of its workforce, or around 200 jobs, as part of a cost-saving effort aimed at stabilising the company. It will also halt work on its therapy development projects, exploring options to license or sell them.
Negative
WSJ
1 month ago
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
Negative
Market Watch
1 month ago
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
Charts implemented using Lightweight Charts™